Our goal is to fulfill its promise.

At Exact Sciences, we’re pioneering a paradigm shift in cancer detection. The Cancerguard™ test in development is being designed to detect multiple cancers in their earliest stages from a single blood draw.1 So we can start to close the gaps that exist in today’s cancer screening.

Because if we can detect cancer early, we may be able to stay one step ahead of it.2,3

See our advancements presented at the European Society of Medical Oncology (ESMO) Congress 2023

The upper hand against cancer

There is a moment when we all have the upper hand against cancer. It’s before the first signs and symptoms show up, when more options are on the table. But too often, early detection opportunities are unavailable or missed.1 Today, we only have routine screening tests for about one-third of diagnosed cancers.2* This means that many cancers go undetected until it’s too late.1

Our vision for the Cancerguard™ test aims to transform cancer screening.

*Calculated using estimated new diagnoses and deaths from cancers that have standard-of-care screening: breast, cervical, colorectal, and lung (high risk) against all sites.

The Cancerguard™ test is under development. The features above describe current development goals. It has not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.


  1. Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018;2:23.
  2. Siegel RL, Miller KD, Wagel NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
  3. Douville C, Nobles C, Hwang HJ, et al. Multi-cancer early detection through evaluation of aneuploidy, methylation, and protein biomarkers in plasma. Poster presented at: ESMO Congress; September 9-13, 2022; Paris, France. Abstract 73P.